Holen Sie sich die Stockscreener-App
8.92
4.90%
-0.46
Handel nachbörslich:
8.84
-0.08
-0.90%
Schlusskurs vom Vortag:
$9.38
Offen:
$8.92
24-Stunden-Volumen:
1,207
Relative Volume:
0.42
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-11.16%
1M Leistung:
-17.79%
6M Leistung:
-38.53%
1J Leistung:
-43.79%
1-Tages-Spanne:
$8.841
$8.965
1-Wochen-Bereich:
$8.841
$9.87
52-Wochen-Spanne:
$8.841
$16.27
Range Cancer Therapeutics Etf Stock (CNCR) Company Profile
Firmenname
Range Cancer Therapeutics Etf
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CNCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNCR
Range Cancer Therapeutics Etf
|
8.92 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
263.96 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
536.70 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
540.07 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
210.85 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
450.66 | 124.43B | 0 | 0 | 0 | 0.00 |
Range Cancer Therapeutics Etf Aktie (CNCR) Neueste Nachrichten
Best Stocks Under $20 Right Now - Benzinga
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - Nasdaq
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - Nasdaq
QQQ ETF News, 3/19/2025 - The Globe and Mail
(CNCR) Proactive Strategies - Stock Traders Daily
Nasdaq Correction: Buy This Unstoppable ETF at a Discount - The Globe and Mail
Buffer ETFs to Consider for Protecting Gains and Limiting Losses - The Globe and Mail
S&P 500 Index Funds Yield Just 1.3%. Consider Buying These 2 Low-Cost Vanguard ETFs to Generate More Passive Income. - The Globe and Mail
VOO ETF News, 3/14/2025 - The Globe and Mail
VOO ETF News, 3/12/2025 - The Globe and Mail
Is the Fidelity High Dividend ETF the Smartest Investment You Can Make Today? - The Globe and Mail
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You? - The Globe and Mail
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy? - The Globe and Mail
SCHD ETF News, 3/11/2025 - The Globe and Mail
1 No-Brainer Artificial Intelligence (AI) ETF to Buy With $40 During the Nasdaq Sell-Off - The Globe and Mail
Why You Can Do Better Than the SPDR S&P 500 ETF Trust - The Globe and Mail
12 Best Stock Scanners and Screeners in March 2025 in March 2025 - Benzinga
Broaden Your ETF Exposure With These 3 Overlooked Funds - The Globe and Mail
(CNCR) Investment Analysis - news.stocktradersdaily.com
7 Best-Performing Biotech ETFs for March 2025 - NerdWallet
Dividend Investing in Canada: Trends, Leaders, and ETF Picks - The Globe and Mail
N2OFF, Inc. Enters Agreement to Acquire MitoCareX Bio Ltd. to Expand Cancer Therapeutics Portfolio - Nasdaq
Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025 - Investing News Network
CIBC Asset Management announces CIBC ETF cash distributions for February 2025 - The Globe and Mail
(CNCR) Trading Signals - Stock Traders Daily
The Unstoppable Momentum in Oncology M&A - Nasdaq
2025 Outlook: Healthcare Technology & Innovation - ETF Trends
This Warren Buffett Index Fund Could Turn $400 Per Month Into $868,200 - The Globe and Mail
Psychedelic ETF PSIL Is 2025's Best-Performing ETF - etf.com
TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright - Armenian Reporter
When (CNCR) Moves Investors should Listen - Stock Traders Daily
SELLAS Life Sciences Group, Inc. Secures $25 Million in Registered Direct Offering for Cancer Therapeutics Development - Nasdaq
Reston Hospital Center adds inpatient unit to expand its range of oncology services - Yahoo Finance
5 US Longevity and Anti-aging Stocks to Watch in 2025 - Investing News Network
NEW: The Most Popular Sponsored Content of 2024 - Visual Capitalist
Looking for Gold Exposure in 2025? 3 ETFs to Consider - The Globe and Mail
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer (LPTX) - Seeking Alpha
Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts (BDTX) - Seeking Alpha
Total World Stock Index ETF Vanguard (VT-A) QuotePress Release - The Globe and Mail
Chevron Corp (CVX-N) QuotePress Release - The Globe and Mail
Texas Instruments (TXN-Q) QuotePress Release - The Globe and Mail
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
When the Price of (CNCR) Talks, People Listen - Stock Traders Daily
Science & Technology | TBR News Media | Page 2 - TBR News Media
PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises - Yahoo Finance
Cutaneous T-Cell Lymphoma Diagnosis Market Set to Surpass US$ 425.8 Million by 2034, States Fact.MR - GlobeNewswire Inc.
(CNCR) Trading Report - Stock Traders Daily
Enbridge Inc (ENB-N) QuotePress Release - The Globe and Mail
Cold Spring Harbor Laboratory - TBR News Media
Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields (NVCR) - Seeking Alpha
Finanzdaten der Range Cancer Therapeutics Etf-Aktie (CNCR)
Es liegen keine Finanzdaten für Range Cancer Therapeutics Etf (CNCR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):